This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.
2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
- May 03, 2012
Targacept Reports First Quarter 2012 Financial Results - April 25, 2012
Targacept Announces Reduction in Force and Plan to Focus Resources on Later-Stage Pipeline - April 24, 2012
Targacept to Report First Quarter 2012 Financial Results on May 3, 2012 - April 10, 2012
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of TC-6987 in Asthma - March 27, 2012
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of TC-6987 - March 20, 2012
AstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy Studies Do Not Meet Primary Endpoint, Regulatory Filing Will Not Be Pursued - February 21, 2012
Targacept Reports Fourth Quarter and 2011 Financial Results - February 07, 2012
Targacept to Report Fourth Quarter and 2011 Financial Results on February 21, 2012 - February 06, 2012
Targacept Announces Participation in Upcoming Conferences - January 05, 2012
Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s Disease - January 04, 2012
Targacept to Present at the 30th Annual J.P. Morgan Healthcare Conference